Results 21 to 30 of about 11,360 (208)

Exploration of in Vivo Efficacy of Artemether-Lumefantrine Against Uncomplicated Plasmodium Falciparum Malaria in Under Fives in Tabora Region, Tanzania. [PDF]

, 2013
Tanzania adopted artemether-lumefantrine (AL) as first-line drug for uncomplicated malaria in 2006. Recently, there was an anecdotal report on high malaria recurrence rate following AL treatment in in the (urban and peri-urban), western part of Tanzania.
Minzi, O.M.S., Abdunoor M Kabanywanyi, Kabanywanyi, A.M., Mugittu, K., Joseph, Deokary, Premji, Zulfiqarali, Mugittu, Kefas, Deokary Joseph, Omary MS Minzi, Kabanywanyi, Abdunoor M, Kefas Mugittu, Ruth Hulser, Zulfiqarali Premji, Joseph, D., Premji, Zul, Hulser, Ruth, Minzi, Omary Ms, Hulser, R.   +17 more
core   +1 more source

Formulation, process development and evaluation of artemether and lumefantrine soft gelatin capsule

Journal of Pharmacy and Bioallied Sciences, 2012
Artemether and Lumefantrine capsules are indicated for the treatment of P. falciparum malaria cases resistant to both chloroquine and sulphadoxine, pyrimethamine combination. Both artemether and lumefantrine act as blood schizontocides.
A Patel, A Lodha, J Chaudhuri, P Jadia, T Joshi, J Dalal   +5 more
doaj   +1 more source

Population Pharmacokinetics and Pharmacodynamics of Artemether and Lumefantrine During Combination Treatment in Children with Uncomplicated Falciparum Malaria in Tanzania. [PDF]

, 2010
The combination of artemether (ARM) and lumefantrine is currently the first-line treatment of uncomplicated falciparum malaria in mainland Tanzania. While the exposure to lumefantrine has been associated with the probability of adequate clinical and ...
Färnert, Anna, Zul Premji, Mårtensson, A, Annerberg, A, Mårtensson, Andreas, Annerberg, A., Andreas Mårtensson, Martensson, A., Bjorkman, A., Ngasala, B., Lindegårdh, N, Hietala, Sofia Friberg, Ngasala, B, Ashton, M., Dahlström, S, Gil, P, Friberg Hietala, Sofia,, Björkman, A, Premji, Z., Björkman, Anders, Sofia Friberg Hietala, Premji, Zul, Farnert, A., Dahlström, Sabina, Hietala, SF, Anna Annerberg, Annerberg, Anna, Anders Björkman, Anna Färnert, Pedro Gil, Lindegårdh, Niklas, Ashton, M, Ngasala, Billy, Michael Ashton, Färnert, A, Niklas Lindegårdh, Dahlstrom, S., Gil, P., Billy Ngasala, Lindegardh, N., Ashton, Michael, Gil, J. P., Premji, Z, Gil, Pedro, Hietala, S.F., Ashton, Michael,, Sabina Dahlström   +46 more
core   +1 more source

Ionic Liquid Forms of the Antimalarial Lumefantrine in Combination with LFCS Type IIIB Lipid-Based Formulations Preferentially Increase Lipid Solubility, In Vitro Solubilization Behavior and In Vivo Exposure

Pharmaceutics, 2019
Lipid based formulations (LBFs) are commonly employed to enhance the absorption of highly lipophilic, poorly water-soluble drugs. However, the utility of LBFs can be limited by low drug solubility in the formulation.
Erin Tay, Tri-Hung Nguyen, Leigh Ford, Hywel D. Williams, Hassan Benameur, Peter J. Scammells, Christopher J. H. Porter   +6 more
doaj   +1 more source

Dispersible formulation of artemether/lumefantrine: specifically developed for infants and young children. [PDF]

, 2009
Infants and children under five years of age are the most vulnerable to malaria with over 1,700 deaths per day from malaria in this group. However, until recently, there were no WHO-endorsed paediatric anti-malarial formulations available.
Abdulla Salim, Sagara, Issaka, Abdulla, Salim, Sagara Issaka, Salim Abdulla, Issaka Sagara   +5 more
core   +2 more sources

Stability-indicating HPLC-DAD/UV-ESI/MS impurity profiling of the anti-malarial drug lumefantrine

Malaria Journal, 2011
Background Lumefantrine (benflumetol) is a fluorene derivative belonging to the aryl amino alcohol class of anti-malarial drugs and is commercially available in fixed combination products with β-artemether.
Duchateau Luc, Burvenich Christian, Van Dorpe Sylvia, Vangheluwe Elien, Baert Bram, Suleman Sultan, Verbeken Mathieu, Jansen Frans H, De Spiegeleer Bart   +8 more
doaj   +1 more source

Population pharmacokinetics of lumefantrine in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Western Kenya. [PDF]

Br J Clin Pharmacol
Aim This study intends to assess the pharmacokinetic properties and treatment response of lumefantrine in pregnant and non‐pregnant women with uncomplicated Plasmodium falciparum malaria infection in Western Kenya. Methods Seventy‐five women with uncomplicated P.
Juma E, Ding J, Ongas M, Koskei N, Onyango K, Oloo F, Aman R, Kokwaro G, Tarning J, Ogutu B.   +9 more
europepmc   +2 more sources

Chlorproguanil−Dapsone−Artesunate versus Artemether−Lumefantrine : a randomized, double-blind phase III trial in African children and adolescents with uncomplicated plasmodium falciparum malaria [PDF]

, 2009
Chlorproguanil−dapsone−artesunate (CDA) was developed as an affordable, simple, fixed-dose artemisinin-based combination therapy for use in Africa. This trial was a randomized parallel-group, double-blind, double-dummy study to compare CDA and artemether−
Peter A Winstanley, Pamba Allan, Guiguemdé, Robert, Stephan Duparc, Paula L Kirby, Esamai, Fabian, Ezedinachi, Emmanuel U, Ward, S.A., Umeh, Rich E., Borrmann Steffen, Winstanley Peter A., Kirby, Paula L., Kellam, Lynda, Premji, Z., Greenwood, Brian, Ward, Stephen A, Premji, Zul, Lynda Kellam, Ezedinachi Emmanuel U., Oguche, Stephen, Owusu-Agyei, S., Stephen Oguche, Greenwood Brian, Oguche Stephen, Owusu-Agyei Seth, Winstanley, Peter A, Oguche, S, Emmanuel U Ezedinachi, Pamba, Allan, Rich E Umeh, Greenwood, B., Umeh Rich E., Zul Premji, Kellam, L., Winstanley, P.A., Duparc, Stephan, Owusu-Agyei, Seth, Duparc Stephan, Guiguemdé Robert, Guiguemde, R., Ward, S. A., Umeh, Rich Enujioke, Allan Pamba, Ward, Steve, Fabian Esamai, Ezedinachi, Emmanuel U., Umeh, R.E., Stephen A Ward, Kellam Lynda, Premji Zul, Esamai Fabian, Duparc, S., Kirby Paula L., Sowunmi Akintunde, Kirby, Paula L, Brian Greenwood, Pamba, A., Kirby, P.L., Rénia, Laurent, Ward Stephen A., Borrmann, S., Seth Owusu-Agyei, Robert Guiguemdé, Akintunde Sowunmi, Sowunmi, Akintunde, Ezedinachi, E.U., Umeh, Rich E, Sowunmi, A., Oguche, S., Borrmann, Steffen, Esamai, F., Steffen Borrmann, Winstanley, Peter, Winstanley, Peter A.   +73 more
core   +1 more source

Efficacy of Artemether-Lumefantrine in Treatment of Malaria Among Under-Fives and Prevalence of Drug Resistance Markers in Igombe-Mwanza, North-Western Tanzania. [PDF]

, 2012
\ud \ud Drug resistance to anti-malarials is a major public health problem worldwide. This study aimed at establishing the efficacy of artemether-lumefantrine (ACT) in Igombe-Mwanza, north-western Tanzania after a few years of ACT use, and establish the ...
Kamugisha, Erasmus, Minde Mercy, Kataraihya Johaness, Kironde, Fred, Kamugisha Erasmus, Erasmus Kamugisha, Jing, Sun, Kongola Gilbert, Mercy Minde, Kironde Fred, Jing Sun, Swedberg, Göte, Johaness Kataraihya, Kataraihya, Johaness, Swedberg Göte, Sun Jing, Gilbert Kongola, Kongola, Gilbert, Minde, Mercy, Fred Kironde, Göte Swedberg   +20 more
core   +1 more source

Evidence for linkage of pfmdr1, pfcrt, and pfk13 polymorphisms to lumefantrine and mefloquine susceptibilities in a Plasmodium falciparum cross

International Journal for Parasitology: Drugs and Drug Resistance, 2020
Background: Lumefantrine and mefloquine are used worldwide in artemisinin-based combination therapy (ACT) of malaria. Better understanding of drug susceptibility and resistance is needed and can be obtained from studies of genetic crosses.
Sean T. Windle, Kristin D. Lane, Nahla B. Gadalla, Anna Liu, Jianbing Mu, Ramoncito L. Caleon, Rifat S. Rahman, Juliana M. Sá, Thomas E. Wellems   +8 more
doaj   +1 more source